InnoCan Pharma Corporation
INNO
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 29.61% | -26.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.61% | -26.88% | |||
| Cost of Revenue | 3.05% | -11.57% | |||
| Gross Profit | 32.96% | -28.44% | |||
| SG&A Expenses | 25.06% | -25.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.69% | -26.49% | |||
| Operating Income | 14.75% | 24.30% | |||
| Income Before Tax | -151.60% | 211.24% | |||
| Income Tax Expenses | 124.43% | -219.09% | |||
| Earnings from Continuing Operations | -147.76% | 212.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -161.43% | 147.46% | |||
| Net Income | -148.72% | 202.47% | |||
| EBIT | 14.75% | 24.30% | |||
| EBITDA | 14.51% | 24.61% | |||
| EPS Basic | -148.53% | 202.89% | |||
| Normalized Basic EPS | -175.16% | 169.22% | |||
| EPS Diluted | -148.53% | 202.89% | |||
| Normalized Diluted EPS | -175.16% | 169.22% | |||
| Average Basic Shares Outstanding | 0.41% | -0.41% | |||
| Average Diluted Shares Outstanding | 0.41% | -0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||